vs
Apyx Medical Corp（APYX）与GLAUKOS Corp（GKOS）财务数据对比。点击上方公司名可切换其他公司
GLAUKOS Corp的季度营收约是Apyx Medical Corp的7.5倍（$143.1M vs $19.2M）。Apyx Medical Corp净利率更高（-6.8% vs -93.4%，领先86.6%）。GLAUKOS Corp同比增速更快（35.7% vs 34.7%）。GLAUKOS Corp自由现金流更多（$3.9M vs $-2.8M）。过去两年Apyx Medical Corp的营收复合增速更高（36.8% vs 29.3%）
Apyx Medical前身是博维医疗，是美国的医疗器械制造商，专注生产电外科产品与能源技术相关医疗设备，公司总部位于佛罗里达州克利尔沃特，在保加利亚设有生产工厂。
Glaukos Corp是一家专注于眼科领域的医疗科技企业，开发并商业化用于治疗青光眼、角膜疾病等眼部病症的微创手术器械、处方药物及消费级产品，主要市场覆盖北美、欧洲及亚太地区，为全球医院、眼科诊所及患者提供服务。
APYX vs GKOS — 直观对比
营收规模更大
GKOS
是对方的7.5倍
$19.2M
营收增速更快
GKOS
高出0.9%
34.7%
净利率更高
APYX
高出86.6%
-93.4%
自由现金流更多
GKOS
多$6.7M
$-2.8M
两年增速更快
APYX
近两年复合增速
29.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $19.2M | $143.1M |
| 净利润 | $-1.3M | $-133.7M |
| 毛利率 | 62.6% | -1.1% |
| 营业利润率 | 0.1% | -97.7% |
| 净利率 | -6.8% | -93.4% |
| 营收同比 | 34.7% | 35.7% |
| 净利润同比 | 71.9% | -298.0% |
| 每股收益（稀释后） | — | $-2.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APYXGKOS
| Q4 25 | $19.2M | $143.1M | ||
| Q3 25 | $12.9M | $133.5M | ||
| Q2 25 | $11.4M | $124.1M | ||
| Q1 25 | $9.4M | $106.7M | ||
| Q4 24 | $14.2M | $105.5M | ||
| Q3 24 | $11.5M | $96.7M | ||
| Q2 24 | $12.1M | $95.7M | ||
| Q1 24 | $10.2M | $85.6M |
净利润APYXGKOS
| Q4 25 | $-1.3M | $-133.7M | ||
| Q3 25 | $-2.0M | $-16.2M | ||
| Q2 25 | $-3.8M | $-19.7M | ||
| Q1 25 | $-4.2M | $-18.1M | ||
| Q4 24 | $-4.6M | $-33.6M | ||
| Q3 24 | $-4.7M | $-21.4M | ||
| Q2 24 | $-6.6M | $-50.5M | ||
| Q1 24 | $-7.6M | $-40.8M |
毛利率APYXGKOS
| Q4 25 | 62.6% | -1.1% | ||
| Q3 25 | 64.4% | 78.4% | ||
| Q2 25 | 62.3% | 78.3% | ||
| Q1 25 | 60.1% | 77.2% | ||
| Q4 24 | 63.0% | 72.9% | ||
| Q3 24 | 60.5% | 76.6% | ||
| Q2 24 | 61.7% | 76.4% | ||
| Q1 24 | 58.1% | 76.3% |
营业利润率APYXGKOS
| Q4 25 | 0.1% | -97.7% | ||
| Q3 25 | -6.5% | -12.3% | ||
| Q2 25 | -22.6% | -18.3% | ||
| Q1 25 | -32.4% | -19.4% | ||
| Q4 24 | -21.4% | -27.2% | ||
| Q3 24 | -31.6% | -25.5% | ||
| Q2 24 | -45.7% | -31.3% | ||
| Q1 24 | -64.6% | -45.6% |
净利率APYXGKOS
| Q4 25 | -6.8% | -93.4% | ||
| Q3 25 | -15.4% | -12.2% | ||
| Q2 25 | -33.2% | -15.8% | ||
| Q1 25 | -44.0% | -17.0% | ||
| Q4 24 | -32.5% | -31.8% | ||
| Q3 24 | -40.9% | -22.1% | ||
| Q2 24 | -54.0% | -52.8% | ||
| Q1 24 | -74.0% | -47.7% |
每股收益（稀释后）APYXGKOS
| Q4 25 | — | $-2.34 | ||
| Q3 25 | — | $-0.28 | ||
| Q2 25 | — | $-0.34 | ||
| Q1 25 | — | $-0.32 | ||
| Q4 24 | — | $-0.56 | ||
| Q3 24 | — | $-0.39 | ||
| Q2 24 | $-0.19 | $-1.00 | ||
| Q1 24 | $-0.22 | $-0.82 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.7M | $90.8M |
| 总债务越低越好 | $37.5M | — |
| 股东权益账面价值 | $14.5M | $656.2M |
| 总资产 | $66.8M | $893.5M |
| 负债/权益比越低杠杆越低 | 2.58× | — |
8季度趋势，按日历期对齐
现金及短期投资APYXGKOS
| Q4 25 | $31.7M | $90.8M | ||
| Q3 25 | $25.1M | $98.2M | ||
| Q2 25 | $29.3M | $100.8M | ||
| Q1 25 | $31.0M | $114.3M | ||
| Q4 24 | $31.7M | $169.6M | ||
| Q3 24 | $28.0M | $100.1M | ||
| Q2 24 | $32.7M | $68.1M | ||
| Q1 24 | $37.3M | $42.5M |
总债务APYXGKOS
| Q4 25 | $37.5M | — | ||
| Q3 25 | $37.5M | — | ||
| Q2 25 | $37.5M | — | ||
| Q1 25 | $37.5M | — | ||
| Q4 24 | $37.5M | — | ||
| Q3 24 | $37.5M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益APYXGKOS
| Q4 25 | $14.5M | $656.2M | ||
| Q3 25 | $5.8M | $769.5M | ||
| Q2 25 | $7.3M | $765.1M | ||
| Q1 25 | $10.5M | $764.0M | ||
| Q4 24 | $14.2M | $766.9M | ||
| Q3 24 | $11.0M | $668.5M | ||
| Q2 24 | $14.7M | $665.2M | ||
| Q1 24 | $20.3M | $450.7M |
总资产APYXGKOS
| Q4 25 | $66.8M | $893.5M | ||
| Q3 25 | $57.4M | $999.4M | ||
| Q2 25 | $58.2M | $987.0M | ||
| Q1 25 | $60.2M | $966.2M | ||
| Q4 24 | $64.8M | $974.8M | ||
| Q3 24 | $60.7M | $926.5M | ||
| Q2 24 | $65.4M | $919.7M | ||
| Q1 24 | $70.7M | $933.3M |
负债/权益比APYXGKOS
| Q4 25 | 2.58× | — | ||
| Q3 25 | 6.41× | — | ||
| Q2 25 | 5.17× | — | ||
| Q1 25 | 3.57× | — | ||
| Q4 24 | 2.64× | — | ||
| Q3 24 | 3.40× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.5M | $6.8M |
| 自由现金流经营现金流 - 资本支出 | $-2.8M | $3.9M |
| 自由现金流率自由现金流/营收 | -14.6% | 2.7% |
| 资本支出强度资本支出/营收 | 1.4% | 2.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-9.1M | $-22.5M |
8季度趋势，按日历期对齐
经营现金流APYXGKOS
| Q4 25 | $-2.5M | $6.8M | ||
| Q3 25 | $-3.5M | $-10.1M | ||
| Q2 25 | $-1.2M | $7.0M | ||
| Q1 25 | $-702.0K | $-18.5M | ||
| Q4 24 | $-2.9M | $507.0K | ||
| Q3 24 | $-4.4M | $-9.6M | ||
| Q2 24 | $-4.3M | $-18.4M | ||
| Q1 24 | $-6.3M | $-33.9M |
自由现金流APYXGKOS
| Q4 25 | $-2.8M | $3.9M | ||
| Q3 25 | $-4.1M | $-11.7M | ||
| Q2 25 | $-1.5M | $5.8M | ||
| Q1 25 | $-757.0K | $-20.5M | ||
| Q4 24 | $-3.2M | $-1.2M | ||
| Q3 24 | $-4.6M | $-11.0M | ||
| Q2 24 | $-4.6M | $-20.5M | ||
| Q1 24 | $-6.4M | $-34.8M |
自由现金流率APYXGKOS
| Q4 25 | -14.6% | 2.7% | ||
| Q3 25 | -31.5% | -8.8% | ||
| Q2 25 | -13.2% | 4.7% | ||
| Q1 25 | -8.0% | -19.2% | ||
| Q4 24 | -22.4% | -1.2% | ||
| Q3 24 | -40.0% | -11.4% | ||
| Q2 24 | -38.0% | -21.4% | ||
| Q1 24 | -62.2% | -40.7% |
资本支出强度APYXGKOS
| Q4 25 | 1.4% | 2.0% | ||
| Q3 25 | 4.0% | 1.2% | ||
| Q2 25 | 2.3% | 0.9% | ||
| Q1 25 | 0.6% | 1.8% | ||
| Q4 24 | 1.7% | 1.6% | ||
| Q3 24 | 1.3% | 1.5% | ||
| Q2 24 | 2.4% | 2.2% | ||
| Q1 24 | 0.3% | 1.1% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APYX
暂无分部数据
GKOS
| Glaucoma | $86.4M | 60% |
| Other | $35.1M | 25% |
| Corneal Health | $21.6M | 15% |
